Gilead Sciences beat earnings estimates in Q2, raised 2025 outlook, and stock near 1-year high.

Gilead Sciences reported second-quarter earnings of $2.01 per share, exceeding estimates by $0.05, with revenue of $7.08 billion, up 1.4% year-over-year. The company raised its 2025 full-year EPS guidance to $7.95–$8.25 and maintains a "Moderate Buy" consensus rating with a target price of $122.61. Despite some insider selling, including CEO Daniel O’Day and executive Johanna Mercier, institutional ownership remains high at 83.67%. The stock, trading near its 1-year high of $124.61, has a market cap of $149.48 billion, a P/E ratio of 24.00, and a PEG ratio of 0.83, reflecting solid financial health and stability.